Already have an account? Sign in.
BofA Upgrades Pharvaris: What Investors Need to Know
BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.
BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.
SpaceX’s Starship upper stage returned from a 22-hour orbital mission and was caught by the launch tower for the first time, marking a key reusability milestone.
The Financial Times reports Amazon is the hyperscaler behind Fermi America’s new 600 MW power deals following the breakdown of 2025 talks.
Meta’s internal prediction market app Takes lets employees bet with credibility points instead of cash. Launch plans remain unclear.
Be the first to know when deals break, stocks move, or biotech headlines hit.